Targeted protein degradation (TPD) mediates protein level through small molecule induced
redirection of E3 ligases to ubiquitinate neo-substrates and mark them for proteasomal …

The use of small molecules to induce targeted protein degradation is increasingly growing in
the drug discovery landscape, and protein degraders have progressed rapidly through the …

Targeted protein degradation has arisen as a powerful therapeutic modality for degrading
disease targets. While proteolysis-targeting chimera (PROTAC) design is more modular, the …

Protein–protein interactions (PPIs) governing the recognition of substrates by E3 ubiquitin
ligases are critical to cellular function. There is significant therapeutic potential in the …

Targeted protein degradation (TPD) is a promising approach in drug discovery for degrading
proteins implicated in diseases. A key step in this process is the formation of a ternary …

Hydroxylation and fluorination of proline alters the pyrrolidine ring pucker and the trans: cis
amide bond ratio in a stereochemistry-dependent fashion, affecting molecular recognition of …

Heterobifunctional proteolysis-targeting chimeric compounds leverage the activity of E3
ligases to induce degradation of target oncoproteins and exhibit potent preclinical antitumor …

Recently, it was reported that expanded r (CAG) triplet repeats (r (CAG) exp) associated with
untreatable neurological diseases cause pre-mRNA mis-splicing likely due to sequestration …

Heterobifunctional chimeric degraders are a class of ligands that recruit target proteins to E3
ubiquitin ligases to drive compound-dependent protein degradation. Advancing from initial …

INTRODUCTION The ubiquitin-proteasome system is the major route through which the cell
achieves selective protein degradation. The E3 ubiquitin ligases are the major determinants …